

Brian J Capaldo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7776825/publications.pdf>

Version: 2024-02-01

21
papers

951
citations

759233

12
h-index

752698

20
g-index

25
all docs

25
docs citations

25
times ranked

1896
citing authors

#	ARTICLE	IF	CITATIONS
1	Nascent Prostate Cancer Heterogeneity Drives Evolution and Resistance to Intense Hormonal Therapy. <i>European Urology</i> , 2021, 80, 746-757.	1.9	50
2	Metastatic Castration-Resistant Prostate Cancer Remains Dependent on Oncogenic Drivers Found in Primary Tumors. <i>JCO Precision Oncology</i> , 2021, 5, 1514-1522.	3.0	6
3	<i>Runx3</i> levels in human hematopoietic progenitors are regulated by aging and dictate erythroid-myeloid balance. <i>Haematologica</i> , 2020, 105, 905-913.	3.5	14
4	Cardiac resynchronization therapy reduces expression of inflammation-promoting genes related to interleukin-1 β in heart failure. <i>Cardiovascular Research</i> , 2020, 116, 1311-1322.	3.8	11
5	MEIS1 down-regulation by MYC mediates prostate cancer development through elevated HOXB13 expression and AR activity. <i>Oncogene</i> , 2020, 39, 5663-5674.	5.9	16
6	Targeting the PI3K/AKT Pathway Overcomes Enzalutamide Resistance by Inhibiting Induction of the Glucocorticoid Receptor. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 1436-1447.	4.1	31
7	Human TH1 and TH2 cells targeting rhinovirus and allergen coordinately promote allergic asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 146, 555-570.	2.9	32
8	An integrated framework using high-dimensional mass cytometry and fluorescent flow cytometry identifies discrete B cell subsets in patients with red meat allergy. <i>Clinical and Experimental Allergy</i> , 2019, 49, 615-625.	2.9	12
9	TH1 signatures are present in the lower airways of children with severe asthma, regardless of allergic status. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 141, 2048-2060.e13.	2.9	103
10	Formation and phenotypic characterization of CD49a, CD49b and CD103 expressing CD8 T cell populations in human metastatic melanoma. <i>Oncolmmunology</i> , 2018, 7, e1490855.	4.6	10
11	Implementation of Mass Cytometry as a Tool for Mechanism of Action Studies in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 2366-2376.	1.9	6
12	Dysregulation of RUNX3 in Aged Human HSPCs May Contribute to Perturbations in Erythropoiesis and Balanced Lineage Output. <i>Blood</i> , 2018, 132, 2553-2553.	1.4	0
13	Microenvironmental agonists generate de novo phenotypic resistance to combined ibrutinib plus venetoclax in CLL and MCL. <i>Blood Advances</i> , 2017, 1, 933-946.	5.2	75
14	Combinatorial drug screening and molecular profiling reveal diverse mechanisms of intrinsic and adaptive resistance to BRAF inhibition in V600E BRAF mutant melanomas. <i>Oncotarget</i> , 2016, 7, 2734-2753.	1.8	19
15	Extrinsic Factors in the In Vivo Macroenvironment Generate Phenotypic Resistance to BTK/Bcl-2 Targeted Therapies in Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma. <i>Blood</i> , 2016, 128, 754-754.	1.4	0
16	Systems Analysis of Adaptive Responses to MAP Kinase Pathway Blockade in BRAF Mutant Melanoma. <i>PLoS ONE</i> , 2015, 10, e0138210.	2.5	9
17	Synergistic apoptosis in head and neck squamous cell carcinoma cells by inhibition of insulin-like growth factor-1 receptor signaling and compensatory signaling pathways. <i>Head and Neck</i> , 2015, 37, 1722-1732.	2.0	6
18	Identification of a New Target of miR-16, Vacuolar Protein Sorting 4a. <i>PLoS ONE</i> , 2014, 9, e101509.	2.5	10

#	ARTICLE	IF	CITATIONS
19	Total Synthesis of a Functional Designer Eukaryotic Chromosome. Science, 2014, 344, 55-58.	12.6	486
20	Synergistic Cytotoxicity of Ibrutinib and the BCL2 Antagonist, ABT-199(GDC-0199) in Mantle Cell Lymphoma (MCL) and Chronic Lymphocytic Leukemia (CLL): Molecular Analysis Reveals Mechanisms of Target Interactions. Blood, 2014, 124, 509-509.	1.4	22
21	Synthetic Lethal Screening with Small-Molecule Inhibitors Provides a Pathway to Rational Combination Therapies for Melanoma. Molecular Cancer Therapeutics, 2012, 11, 2505-2515.	4.1	32